Truist raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- FDA says Boston Scientific Accolade pacemakers may need early replacement
- Boston Scientific price target raised to $110 from $100 at TD Cowen
- Boston Scientific price target raised to $107 from $98 at Citi
- Boston Scientific price target raised to $101 from $98 at Canaccord
- Boston Scientific participates in a conference call with Truist